Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine

Vaccine

Volumn 16, Issue 20, 1998, Pages 1982-1989

  Koike, Yuko ^a   Yoo, Yung Choon ^a   Mitobe, Manabu ^a   Oka, Tetsuya ^b   Okuma, Kunio ^b   Tono Oka, Shuichi ^a   Azuma, Ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Adjuvant; BCG CWS; Hepatitis B surface antigen; MDP; TDM

Indexed keywords

BCG VACCINE; CORD FACTOR; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MURAMYL DIPEPTIDE DERIVATIVE; RECOMBINANT HEPATITIS B SURFACE ANTIGEN VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CELL WALL; CORD FACTORS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

EID: 0032387991     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00084-X     Document Type: Article

References (44)

1. 1 Gupta, R.K., Relyvelt, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S. and Gupta, C.K. Adjuvant-a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306.
2. 2 Andre, F.E. and Salary, A. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad. J. 1987, 63(Suppl. 2), 169-177.
3. 3 Freund, J. The mode of action of immunologic adjuvants. Adv. Tuberc. Res. 1956, 7, 130-148.
4. 4 Munoz, J. Adjuvant effects of mycobacterta and endotoxin in antibody response. Adv. Immunol. 1964, 4, 397-440.
5. 5 Azuma, I., Kanetsuna, F., Taniyama, T., Yamamura, Y., Hori, M. and Tanaka, Y. Adjuvant activity of mycobacterial fractions. I. Purification and in vitro adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8. Biken J. 1975, 18, 1-13.
6. 6 Azuma, I., Kishimoto, S., Yamamura, Y. and Petit, J.-F. Adjuvanticity of mycobacterial cell walls. Jpn. J. Microbiol. 1971, 15, 193-197.
7. 7 Azuma, I., Tanimura, T., Sugimura, K., Aladin, A.A. and Yamamura, Y. Mitogenic activity of the cell walls of mycobacteria, nocardia, corynebacteria and anaerobic coryneforms. Jpn. J. Microbiol. 1976, 20, 263-271.
8. 8 Azuma, I., Tanimura, T., Yamawaki, M., Sugimura, K. and Yamamura, Y. Adjuvant and antitumour activities of Nocardia cell-wall skeletons. Gann 1976, 57, 733-736.
9. 9 Kitagawa, M., Hamaoka, T., Haba, S., Takatsu, K. and Masaki, H. Selective suppression of T-cell activity in tumor-bearing host and attempt for its improvement. In: Host Defense against Cancer and its Potentiation (Eds Mizuno, D. et al.). Japan Scientific Societies Press, Tokyo, 1975, pp. 31-42.
10. 10 Ohno, R., Ezaki, K. and Kobayashi, M. et al. Immune response of regional Lymph node to BCG-CWS cell-wall skeleton and other immunopotentiators. GANN Monogr. Cancer Res. 1978, 21, 109-126.
11. 11 Orita, K., Mannami, T. and Miwa, H. et al. Immunotherapy with BCG and BCG cell-wall skeleton against advanced gastric cancer and colo-rectal cancer. GANN Monogr. Cancer Res. 1978, 21, 163-171.
12. 12 Sugimura, K., Uemiya, M., Yamawaki, M., Azuma, I. and Yamamura, Y. Macrophage dependency of T-lymphocyte mitogenicity by Nocardia rubra cell-wall skeleton. Microbiol. Immunol. 1977, 21, 525-530.
13. 13 Taniyama, T., Azuma, I., Aladin, A.A. and Yamamura, Y. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxity in tumor-bearing mice. Gann 1976, 66, 705-709.
14. 14 Taniyama, T., Azuma, I. and Yamamura, Y. Adjuvant activity of mycobacterial fractions. III. Adjuvant effect of cell walls of Mycobacterium bovis BCG on cell-mediated cytotoxicity in mice. Jpn. J. Microbiol. 1975, 19, 255-264.
15. 15 Taniyama, T., Watanabe, T., Azuma, I. and Yamamura, Y. Adjuvant activity of mycobacterial fractions. II. In vitro adjuvant activity of cell walls of mycobacteria, nocardia and corynebacteria. Jpn. J. Microbiol. 1974, 18, 415.
16. 16 Azuma, I. and Yamamura, Y. Immunotherapy of cancer with BCG cell-wall skeleton and related materials. Gann Monogr. Cancer Res. 1979, 24, 121-141.
17. 17 Azuma, I., Taniyama, T., Hirao, F. and Yamamura, Y. Antitumor activity of cell-wall skeletons and peptidoglycolopids of mycobacteria and related microorganism. Gann 1974, 65, 493-505.
18. 18 Ogura, T., Namba, M., Hirao, F., Yamawaki, M., Azuma, I. and Yamamura, Y. Effect of BCG cell-wall skeleton on metastasis of syngeneic tumor in rats, with special reference to lymphocytes trapping. Gann 1978, 69, 311-315.
19. 19 Meyer, T.J., Ribi, E.E., Azuma, I. and Zbar, B. Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J. Natl Cancer Inst. 1974, 52, 103-111.
20. 20 Tokuzen, R., Okabe, M., Azuma, I. and Yamamura, Y. Effect of Nocardia and Mycobacterium cell-wall skeletons on autochthonous tumor grafts. Gann 1975, 66, 433-435.
21. 21 Toshimoto, Y. Effect of oil-attached BCG cell-wall skeleton on the induction of pleural fibrosarcoma in mice. Gann 1976, 67, 441-445.
22. 22 Kuwamura, S. Studies on the relationship between the induction of primary hepatic carcinoma by 3′-methyl-4-dimethylaminoazobenzene and cell-mediated immunity in hosts. J. Osaka City Med. Cent. 1977, 26, 145-157.
23. 23 Hirao, F., Nishikawa, H. and Yasaki, S. et al. Effect of oil-attached BCG cell-wall skeleton and thymectomy on the incidence of lung cancer and amyloidosis induced by chemical carcinogens in rabbits. Gann 1978, 69, 453-459.
24. 24 Yamamura, Y., Sakatani, M., Ogura, T. and Azuma, I. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer 1979, 43, 1314-1319.
25. 25 Hayashi, A. and Noda, A. Does the cell wall skeleton from Bacille Calmette-Guerin directly induce interferon-gamma, independent of interleukin-12?. Jpn. J. Clin. Oncol. 1996, 26, 124-127.
26. 26 Bloch, H. Studies on the virulence of tubercle bacilli. Isolation and biological properties of a constituent of virulent organism. J. Exp. Med. 1950, 91, 197-217.
27. 27 Noll, H., Bloch, H., Asselineau, J. and Lederer, E. The chemical structure of the cord factor of Mycobacterium tuberculosis. Biochim. Biophys. Acta 1956, 20, 299-399.
28. 28 Lemaire, G., Tenu, J.-P., Petit, J.-F. and Lederer, E. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 1986, 6, 243-272.
29. 29 Numata, F., Nishimura, K. and Ishida, H. et al. Lethal and adjuvant activities of cord factor (trehalose-6,6′-dimycolate) and synthetic analogs in mice. Chem. Pharm. Bull. 1985, 33, 4544-4555.
30. 30 Azuma, I. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 1992, 10, 1000-1006.
31. 31 Yoo, Y.C., Saiki, I., Sato, K. and Azuma, I. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-hematogenous tumors in mice. Vaccine 1992, 12, 175-180.
32. 32 Tamura, M., Yoo, Y.C. and Yoshimatsu, K. et al. Effect of muramyl dipeptide derivatives as adjuvants on induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 1995, 13, 77-82.
33. 33 Yoo, Y.C., Yoshimatsu, K. and Koike, Y. et al. Adjuvant activity of muramyl dipeptides to enhance immunogenicity of a hantavirus inactivated vaccine. Vaccine 1998, 16, 216-224.
34. 34 Audibert, F.M. and Lise, L.D. Adjuvant: current status, clinical perspectives and future prospects. Immunol. Today 1993, 14, 281-284.
35. 35 Veien, N.K., Hattel, T., Justesen, O. and Norholm, A. Aluminium allergy. Contact Dermatitis 1986, 15, 295-597.
36. 36 Nagel, J., Svec, D., Water, T. and Fireman, P. IgE synthesis in man: I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J. Immunol. 1977, 118, 334-341.
37. 37 Mitani, S., Yamamoto, H., Ikegami, H., Usui, M. and Matsuhashi, T. Immunoglobulin E-suppressing and immunogloblin G-enhancing tetanus toxoid prepared by conjugation with Pullulan. Infect. Immun. 1982, 36, 971-976.
38. 38 Lovgren, K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988, 27, 241-245.
39. 39 Pyle, S.W., Morein, B. and Bess, J.W. Jr.Jr et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficient virus type 1 (HIV-1) or HIV-1 external envelope glycoprotein (GP120). Vaccine 1989, 7, 465-473.
40. 40 Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.P. Enhancement of antibody response to influenza B virus haemaggulutinin by use of a new adjuvant formulation. Vaccine 1990, 8, 49-56.
41. 41 Byars, N.E., Kaneko, G., Welch, M., Lehman, D. and Allison, A.C. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine 1991, 9, 309-318.
42. 42 Haigwood, N.L., Nara, P.L. and Brooks, E. et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 1992, 66, 172-182.
43. 43 Okuyama, H. and Morikawa, K. Histological study on adjuvanticity of BCG-cell wall: comparison of adjuvanticity between oil-in-water and water-in-oil forms. GANN Monogr. Cancer Res. 1978, 21, 87-91.
44. 44 Powrie, F. and Coffman, R.L. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol. Today 1993, 14, 270-274.